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UPPER GASTROINTESTINAL BLEEDING — STATE OF THE ART
Abstract: Upper gastrointestinal (GI) bleeding is a condition requiring immediate medical intervention, 
with high associated mortality exceeding 10%. The most common cause of upper GI bleeding is peptic 
ulcer disease, which largely corresponds to the intake of NSAIDs and Helicobacter pylori infection. 
Endoscopy is the essential tool for the diagnosis and treatment of active upper GI hemorrhage. 
Endoscopic therapy together with proton pump inhibitors and eradication of Helicobacter pylori 
significantly reduces rebleeding rates, mortality and number of emergency surgical interventions. 
This paper presents contemporary data on the diagnosis and treatment of upper gastrointestinal 
bleeding.
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INTRODUCTION
Obtaining data on the incidence of upper GI bleeding in Poland and the number 
of hospitalizations for this reason is complex. Categorization of diseases according 
to ICD-10 catalog extracts some diseases that cause GI bleeding; however system 
of reimbursement of medical expenses based on Homogeneous Groups of Patients 
(HGP) often leads to a distortion of these data. According to the data obtained 
this way there were 31,927 patients in 2009 and 27,280 patients in 2013 hos-
pitalized due to GI bleeding and categorized into HGP F62 (Large and therapeu-
tic endoscopic procedures in GI bleeding), F63 (Mid and diagnostic endoscopic 
procedures in GI bleeding) and F66 (GI bleeding — conservative treatment) [1].
The summary of these data suggest that the incidence of GI bleeding in Po-
land and other countries decreases, affecting 83/100000 inhabitants in 2009 and 
only approximately 72/100,000 inhabitants in 2013. No change in ratios within 
morbidity in women (40%) and men (60%) has been observed. In the US, upper 
GI bleedings account for 400,000 hospitalizations per year with the total hospital 
costs and work absence reaching nearly 2 trillion dollars [2]. The incidence of 
hospitalization for GI bleeding is steadily decreasing [2–5]. The etiology of bleeding 
ulcer is associated with increasing use of non-steroidal anti-inflammatory drugs 
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(NSAIDs) and Helicobacter pylori infection [1, 2]. Men are twice as likely to have 
GI bleeding, and its incidence increases with the age of patients. Recurrence of 
bleeding occurs in about 15% of hospitalized patients and is associated with more 
than 10% mortality [1, 2, 6].
ETIOLOGy 
Upper GI bleeding, which source is located from the esophagus to the ligament 
of Treitz is caused in 50–70% of cases by gastric and duodenal ulcer [1–3, 5, 6]. 
Other cases are usually related to hemorrhagic gastritis and duodenitis (10–20%), 
esophageal varices (3–10%), Mallory-Weiss tear (3–7%), malignancy (approx. 2%) 
and vascular malformations (2–10%). In a few percent of cases one fails to rec-
ognize the source of bleeding [1, 7] (Table 1).
T a b l e  1
Common causes of upper gastrointestinal hemorrhage.
Etiology Incidence (%) Mortality (%)
Peptic ulcer 20–60 4–6
Erosions 7–30 0–1
Varices 4–20 30–50
Esophagitis 3–15 0–1
Mallory-Weiss 4–15 0–2
Vascular malformations 2–5
Malignancies 1–5 20–40
Others <2 2–8
Not known <3
Duodenal peptic ulcers occur more frequently (approximately 55%), but are 
less likely the cause of hospitalization (38%). According to American sources, 
mortality caused by bleeding from duodenal and gastric ulcers is 3.7% and 2.1%, 
respectively. The reason for this is the proximity of the posterior wall of the du-
odenum with large vessels and hence, more dynamic bleeding [1, 8]. 
P e p t i c  u l c e r  is a distinct breach in the mucosal lining of the GI tract which 
penetrates through the muscularis mucosae and lamina propria (Fig. 1, Fig. 2). 
This mucosal defect is accompanied by inflammatory infiltration with deeper tis-
sue necrosis. Local progressive necrosis may involve arterial and venous walls, 
causing interruption of their continuity with subsequent bleeding. Peptic ulcer 
may bleed from the surface or edges of the ulcer bed, but also from a vessel 
within its niche. A meta-analysis of 16 studies involving more than 1600 patients 
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Fig. 1. Gastric ulcer.
Fig. 2. Duodenal ulcer covered with a clot.
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taking NSAIDs showed that the additional Helicobacter pylori infection increas-
es the risk of GI bleeding (OR = 6.1) [9]. The bacteria adhering to the mucosa 
make it more vulnerable to the action of enzymes and toxins, which results in 
increased levels of gastrin and acid concentration in the stomach. 
E r o s i o n s  are shallow epithelial defects and a symptom of acute mucosal 
inflammation. The inflammatory process can appear as acute hemorrhagic gas-
tritis or duodenitis (Fig. 3). It reveals the presence of numerous reddish spots 
that are bleeding or covered with small clots. The factors that cause this inflam-
mation may be chemicals (including drugs and alcohol), bacteria, toxins, stress, 
and certain neurological diseases [2]. The extent of pathologic changes depends 
on the type of inducing agent, its amount and concentration and duration of 
action.
E s o p h a g e a l  v a r i c e s  are running superficially in the mucosa and sub-
mucosa dilated veins.
These venous dilations occur due to a medical condition located outside the 
gastrointestinal tract and are usually discussed as a separate disease entity 
[2, 10]. Esophageal varices are a major complication of portal hypertension which 
is most frequently the result of liver cirrhosis. Blood flow through the hepat-
ic portal system is then redirected from the liver into areas with lower venous 
pressures. This means that collateral circulation develops in the lower esopha-
gus and stomach draining blood to azygos vein. The small blood vessels in these 
areas become distended, becoming more thin-walled, and appear as varicosities. 
A sudden rise in venous pressure combined with a weakening of the walls to 
stretching, evokes variceal rupture and hemorrhage. On endoscopy varices ap-
pear as swollen veins with one or more prominent cherry-red spots from which 
blood flows in a continuous stream. Varices collapse after bleeding and hence it 
is hard to accurately locate the site of variceal rupture. 
The longitudinal rupture of the mucosal lining in the lower part of the esopha-
gus at the junction with gastric cardia is referred to as Mallory-Weiss tear (Fig. 4). 
Damage to the wall may reach the submucosa, muscularis propria, and in ex-
ceptional cases involve its full thickness leading to mediastinitis. Bleeding occurs 
most frequently at the end of vomiting, and its intensity depends on the size of 
the disrupted vessel, and the amount and depth of the mucosal breaks [3, 5, 11]. 
A clot located in the area of gastric cardia with a tiny blood leakage underneath 
is the most common endoscopic image of such a tear. 
Esophagitis is evoked by gastroesophageal reflux disease, infection, drugs, 
radiation and burns [2] (Fig. 5). It frequently involves the lower portion of the 
esophagus, and usually does not require endoscopic intervention. 
N e o p l a s t i c  i n f i l t r a t i o n  is the most common cause of slowly progressive 
anemization related to minor surface damage of the infiltrate with macroscopically 
inconspicuous bleeding (Fig. 6). The intensity of bleeding from neoplastic infiltrate 
depends on its extent, diameter and number of damaged vessels. Endoscopic 
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Fig. 3. Hemorrhagic gastric erosions.
Fig. 4. Mallory-Weiss tear.
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Fig. 5. Esophagitis.
Fig. 6. Gastric cancer.
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picture shows gastric wall tumor with foci of necrosis, partly covered with clots 
and fresh blood sipping underneath. The characteristic feature is the fragility of 
the mucosa and bleeding on contact with an endoscope.
Vascular malformations are disorders of vascular architecture, consisting 
of capillaries or small venous vessels. Arterial blood flowing through capillaries 
under high pressure may lead to their dilation and formation of haemangiomas, 
which may rupture. They are identified during routine endoscopy as a vivid red, 
flat or slightly elevated spots with irregular margins. If they bleed, a clot is formed 
on their surface, similar to the one observed in bleeding ulcer.
Another type of vascular malformation is superficially running submucosal ar-
tery, which under the influence of intense wall contractions can lacerate, leading 
to abundant hemorrhage. On endoscopy, a pulsating arterial blood flow can be 
seen, without any accompanying alterations on mucosal surface. This pathology 
referred to as Dieulafoy’s lesion can occur in all parts of the GI tract, usually in 
the upper part of the stomach and in males.
DIAGNOSIS
Immediate initial clinical assessment of the patient’s general condition and the 
possible resuscitation in hemodynamically unstable patients should be preced-
ed by diagnostic proceedings [1, 8, 10, 11]. In case of massive vomiting patients 
may require endotracheal intubation in order to protect them against aspiration 
of bloody content. These patients require treatment in intensive care units, and 
further diagnostic tests to help determine the source of bleeding. 
Relevant information is obtained from the patient such as upper abdominal 
pain, bloody or coffee ground vomiting, black tarry stools, rectal bleeding and pain 
in the chest. One must pay attention to medications taken by patients prior to 
admission, especially anticoagulants such as warfarin and clopidogrel, NSAIDs, 
aspirin and steroids, as they can adversely affect hemostasis. Patient’s history in 
terms of digestive ulcers, previous GI bleeding, alcohol abuse, drugs, diabetes, 
atherosclerosis, chronic renal failure, chronic liver disease or obstructive lung 
disease are also important. During GI bleeding hemodynamic parameters may 
be normal, however, if its intensity grows, tachycardia and decrease of systolic 
blood pressure ensue. Orthostatic syncope may occur. Physical examination may 
reveal scars after previous abdominal surgery, stimulation of intestinal peristal-
sis, abdominal tension and signs of liver cirrhosis. Digital rectal examination is 
helpful to confirm the presence of black tarry stools or blood. 
Basic l a b o r a t o r y  t e s t s  should include complete blood count, levels of 
potassium, urea and creatinine, coagulation parameters and liver function tests 
[2, 8, 12–14]. Reduced red blood count, lower hemoglobin and hematocrit lev-
els indicate anemia, what indirectly suggests that onset of bleeding was at least 
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12 hours prior to admission, and that the dynamics of the bleeding is not severe 
and adaptive mechanisms of the body help to refill the vascular bed. In addition 
to basic life support, treatment begins with crystalloids infusion, proton pump 
inhibitors given intravenously and blood transfusion if a decrease in hemoglobin 
concentration is less than 7 g/dL [2, 14, 15]. Blood transfusion is an unfavor-
able prognostic factor. The need for blood transfusion in the first 12 hours after 
admission to hospital doubles the risk of rebleeding and increases mortality up 
to 28% in patients bleeding from a peptic ulcer niche [2, 15].
NASOGASTRIC TUBE
A simple method to distinguish between bleeding from the upper and lower GI 
tract is still the insertion of the nasogastric tube in order to aspirate the gastric 
content. The presence of bloody or coffee-ground content confirms the diagnosis. 
However, it should be remembered that the lack of such a content in the tube 
does not exclude bleeding from the upper GI tract [2, 16].
ENDOSCOPy
Endoscopic examination of the esophagus, stomach and duodenum must be per-
formed within 24 hours in hemodynamically stable patients, while in unstable 
patients as soon as possible [2, 7, 8, 10, 15–17]. 
In more than 90% of the cases endoscopy allows to locate the source of bleed-
ing, assess its intensity, and stop it. To assess the intensity of bleeding a modi-
fied classification of Forrest is used for almost 40 years and differentiates active 
hemorrhage images from signs of recent hemorrhage. According to this classifica-
tion stage Ia — active arterial bleeding, Ib — venous bleeding, IIa — visible vessel 
without active bleeding, IIb — adherent clot, IIc — flat pigmented hematin on ulcer 
base, III — lesions without signs of recent hemorrhage or fibrin-covered clean ulcer 
base. The intensity of bleeding classified as Ia, Ib and IIa requires prompt endo-
scopic treatment. The risk of rebleeding without the use of endoscopic hemostasis 
is almost 100% in Ia, 80% in Ib, 20–40% in II, and 3% in III [2, 7, 12, 14, 19–21] 
(Table 2). The introduction of endoscopic hemostasis techniques has led to reduc-
tion in mortality, rebleeding rates, hospital stay duration and number of emergency 
operations. 
Administration of prokinetic drugs (erythromycin, metoclopramide) before en-
doscopic procedure accelerates gastric emptying making endoscopy easier to han-
dle and thus reduces the need to perform repeated endoscopies in cases of diag-
nostic difficulties. The use of these drugs does not influence treatment outcomes 
[14, 22].
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T a b l e  2
Risk of peptic ulcer rebleeding with reference to endoscopic picture.
Endoscopic picture Incidence
Rebleeding without 
endoscopic
Therapy
Rebleeding  
with efficacious  
endoscopic therapy
Spurting (Forrest Ia) 12% 100% 15–30%
Oozing (Forrest Ib) 14%  80% 15–30%
Visible vessel (Forrest IIa) 22%  50% 5%
Adherent clot (Forrest IIb) 10%  33%
Haematin covered flat spot
(Forrest IIc)
10%   7%
Clean bed of ulcer
(Forrest III)
32%   3%
It is possible to stop bleeding with a variety of endoscopic techniques that are 
further divided into thermal, chemical and mechanical modalities. Among thermal 
methods we can distinguish thermal laser photocoagulation and argon plasma 
coagulation as well as mono-, bi- and multipolar electrocoagulation, heat probe 
and microwave probe. Chemical methods include injection of vasoconstrictive 
agents, mainly epinephrine, sclerosants, thrombin and tissue adhesives. Mechan-
ical methods include hemoclips, elastic endoscopic ligatures and loops. Presen-
tation of all available techniques exceeds the size of this survey, however several 
of them will be discussed [2, 7, 14, 17, 19, 20–24].
Argon plasma coagulation (APC) is a contactless equivalent to monopo-
lar coagulation, wherein argon gas is a carrier of electrical charge between the 
passive electrode attached to the patient externally and the active one supplying 
electric charge. 
The transformation of electrical energy into heat occurs in place where the 
active electrode contacts with tissue, leading to localized coagulation. The argon, 
passed down an electrode catheter and energized with an intelligent-circuitry 
electrosurgical unit and patient plate, ionizes to produce a local plasma arc. The 
heating effect is inherently superficial (2–3 mm at most, unless current is ap-
plied in the same place for many seconds) because tissue coagulation increases 
resistance and causes the plasma arc to jump elsewhere. The distance from the 
end of the probe to the tissue is 2–10 mm. The dispersion of the electric charge 
occurs on a broad area like a spray. The depth of coagulation depends on the 
parameters of the generator (standard 60–90 W) and does not exceed 2–3 mm. 
This is particularly important in bleeding from the esophagus and duodenum, 
where the thin wall of the organ may perforate. The stream of electric charge 
finds the shortest way giving the possibility for tissue coagulation of places lo-
cated laterally from the axis of the probe. 
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Inserting a probe ended with a steel needle through the channel of the en-
doscope permits submucosal injection of a sclerosant in bleeding site and sur-
rounding area to obtain hemostasis. Epinephrine is most commonly used and 
applied in saline solution (ratio of 1 : 10,000). It evokes vasoconstrictive effect 
at the injection site, which is maintained for approximately 2 hours. Moreover, 
epinephrine increases platelet aggregation and locally compresses larger vessels 
via mechanical action. Epinephrine is applied in 1 mL aliquots around the base 
of the bleeding site, up to a total of 10–20 mL.
H e m o s t a t i c  c l i p s  are also inserted through the channel of the endo-
scope. After identifying the bleeding vessel, a clip is opened, pressed into the 
vessel, and then clamped and disengaged from the probe. Clips are available in 
different clip arm lengths (6–10 mm). Metal clips cause mechanical pressure on 
the tissue and the vessel.
According to the latest available data, various endoscopic techniques must be 
associated with each other. Cochrane review of publications including 18 random-
ized trials on patients with bleeding peptic ulcers shows that an additional method 
of hemostasis combined with epinephrine solution injection reduces the incidence 
of rebleeding from 18.5 to 10 per cent and mortality from 4.7 to 2.5% [23–25].
The aforementioned methods are mainly used for endoscopic bleeding control 
regarding ulcerations. Most bleedings from mucosal tears in Mallory-Weiss cease 
spontaneously, but in the case of active bleeding, one of the endoscopic methods 
should be applied. In the event of bleeding from vascular malformations argon 
plasma coagulation and clips are applied most commonly. Dieulafoy’s lesion with 
active hemorrhage can be controlled with clips or ligation. Neoplastic infiltration 
with bleeding, due to its size, is most often subjected to argon ablation. Because 
of its tissue friability other methods are usually ineffective [2, 7, 25]. 
The effectiveness of various endoscopic procedures is comparable and depends 
on the cause of bleeding, its intensity, general health status of the patient, and 
the experience of the physician. Initial hemostasis is achieved in 88–95% of pa-
tients. Approximately 10–20% of patients have early recurrence of bleeding requir-
ing intervention, usually endoscopic. Endoscopic methods lead finally to bleeding 
cessation in 80–90% of patients with active hemorrhage [2, 7, 14, 19–25]. The 
primary disadvantage of endoscopic procedure is the possibility of tracheobron-
chial aspiration and perforation of the GI tract.
RADIOLOGy
Radiological diagnosis and treatment is used in cases where the endoscopic man-
agement alone is not effective. Angiography of the celiac trunk is essential and al-
lows locating the site of bleeding and closing it. Vasopressin (0.2–0.4 U/30 minutes) 
is injected via angiographic catheter that is positioned in close proximity to the 
69
bleeding site and then angiographic control is performed. If a bleeding advances, 
vasopressin infusion must be applied for 6–12 hours. In order to counteract the 
side effects of systemic vasopressin action, a simultaneous nitroglycerin infusion 
is recommended. Vasopressin infusion is effective in 50–80% of patients; however, 
nearly 50% have early recurrence of bleeding. Another method is highly selective 
embolization of the bleeding vessel with embolic agent. Embolic agents include 
temporary materials such as gelatin sponge (e.g., Gelfoam), oxidized cellulose or 
polyvinyl alcohol. Complications such as mesenteric artery thrombosis and intes-
tinal wall ischemia occur in about 3% of patients. The effectiveness of radiologi-
cal methods for bleeding control is technically 92–100%, but only 50–94% clin-
ically. Rebleeding occurs in 9–47% of patients. The drawbacks of arteriography 
are the possibility of kidney damage by the administered contrast agent, allergic 
reaction to injected agent, exposure to radiation, and bleeding from the site of 
vascular access [2, 14, 25].
SURGERy
The ineffectiveness of the above mentioned methods, symptoms of bleeding, and 
situations where the patient requires more than 6 units of blood to be trans-
fused are indication for prompt surgical treatment. The emergency surgery rate 
for peptic ulcer bleeding control has decreased in recent years, and according 
to the British data has fallen from 8% in 1993 to 2% in 2006, and according to 
the US data from 21% to 9%, respectively [4, 5].
The course of operation depends on the cause of bleeding, patient’s general 
condition, the mode of performed surgery and the surgeon’s experience. Surgery 
may be impeded by excessive air filling of the intestines and the possibility of 
iatrogenic damage to the mucosa after endoscopic procedure and coagulopathy 
after numerous blood transfusions. 
The bleeding peptic ulcer in the stomach is usually treated surgically by partial 
gastric resection with the ulcer niche. Restoration of gastrointestinal continuity 
depends on the anatomical conditions and aims to restore them as closely as pos-
sible. Surgical control of bleeding from duodenal ulcer niche involves duodenoto-
my and undersewing of a bleeding vessel, followed by pyloroplasty. Sometimes, in 
case of extensive ulcerations involving pylorus, antrectomy is performed. In the 
era of proton pump inhibitors transection of vagal trunks under the diaphragm 
is not a recommended procedure, whereas in the post-operative management it 
is advisable to block the gastric secretion.
Bleeding from the neoplastic infiltration may require surgical treatment. It 
involves the removal of all or part of the stomach and a cancerous tumor with 
disease-free margins and subsequent restoration of the continuity of the gastroin-
testinal tract. Efficacy of bleeding cessation after surgery is 70–100%. Recurrence 
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of bleeding occurs in less than 5% of patients treated surgically, but the periop-
erative mortality rate is between 10 and 50% [2, 14, 25].
PHARMACOTHERAPy
Targeted pharmacotherapy is essential in the treatment of bleeding from upper GI 
tract. Patients with symptoms of bleeding should be given 80 mg pantoprazole, 
omeprazole or esomeprazole intravenously (bolus), followed by continued infusion 
at a dose of 8 mg/hour until the endoscopic diagnosis of the bleeding source is 
made and in case of its confirmation continued until 72 hours after the endo-
scopic bleeding cessation [2, 14, 25, 26]. Cochrane systematic review of litera-
ture on the basis of 6 randomized clinical trials showed no statistical difference 
in the mortality rate, recurrent bleedings and frequency of emergency surgical 
procedures after initial use of PPI relative to the control group (placebo or hista-
mine receptor blockers). However, patients receiving PPI rarely had a history of 
endoscopic signs of bleeding (37.2% vs. 46.5%) (OR = 0.67) and required fewer 
endoscopic controls (8.6% vs 11.7%) (OR = 0.68) [27].
RECURRENT BLEEDING
Symptoms of bleeding after endoscopic examination or treatment and hemody-
namic disturbances suggest recurrence of bleeding. Rebleeding is more frequent 
in patients in whom active bleeding was observed on endoscopy, in patients aged 
over 60 years, manifesting symptoms of shock on admission, with a baseline he-
moglobin level below 10 g/dL. Diameter 20 mm and above of the ulcer niche or 
multiple ulcers are factors that predispose to rebleeding [2, 13, 14, 25]. Large 
ulcers on the posterior wall of the duodenal bulb and the lesser curvature of 
the stomach can penetrate down to gastroduodenal or left gastric artery, making 
endoscopic treatment ineffective.
Rockall risk scoring system attempts to identify patients at risk of adverse 
outcome following acute upper gastrointestinal bleeding (Table 3). Rockall risk 
scoring system has been widely used mainly in the US for nearly 20 years [12]. 
This scoring system uses clinical criteria (increasing age, co-morbidity, shock) as 
well as endoscopic finding (diagnosis, stigmata of acute bleeding). According to 
this score, patients with no evidence of active bleeding with a low risk of recur-
rent bleeding may leave the hospital on the day of diagnosis, and patients with 
a high risk of recurrence of bleeding should undergo endoscopy inspection next day. 
In Europe, the more popular Glasgow-Blatchford bleeding score (GBS) takes 
into account the level of urea in the blood, hemoglobin, systolic blood pressure, 
heart rate, presence of tarry stools and syncope, positive medical history of liver 
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T a b l e  3
Rockall risk scoring system for assessment after an episode of acute upper GI bleeding [12].
Age
younger than  
60 years
60 to 79 years
80 years  
or older
—
Shock symptoms,
systolic Blood 
pressure, heart 
rate
Shock absent, 
blood pressure 
100 mm Hg  
or greater, heart 
rate 100 bpm  
or greater
Tachycardia, 
blood pressure 
100 mm Hg  
or greater, heart 
rate 100 bpm  
or greater
Hypotension, 
blood pressure 
less than  
100 mm Hg
—
Comorbidities No major comor-
bidity
—
Heart failure, 
coronary artery 
disease, any  
major comorbidity
Renal failure, 
liver failure, 
disseminated 
malignancy
Endoscopic  
diagnosis
Mallory-Weiss 
tear or no lesion 
identified, and 
no stigmata  
of recent  
hemorrhage
All other dia-
gnoses
Malignancy of 
upper GI tact
—
Stigmata 
of recent 
hemorrhage
None or dark 
spot only
—
Blood in upper 
GI tract, adherent 
clot, visible or 
spurting vessel
—
Risk of rebleeding and mortality based on Rockall Risk Score:
Score
Risk 0 1 2 3 4 5 6 7 >8
Rebleeding (%) 4.9 3.4 5.3 11.2 14.1 24.1 32.9 43.8 41.8
Mortality (%) 0 0 0.2 2.9 5.3 10.8 17.3 27.0 41.1
bpm = beats per minute
failure and coronary heart disease [13] (Table 4). GBS is able to determine more 
precisely the patients who may require re-intervention, particularly those in which 
the dynamics of bleeding was not high. Based on this scale 16–25% of patients 
with symptoms of bleeding can be early discharged from hospital. Recurrence of 
bleeding is an indication to re-take e n d o s c o p i c  t r e a t m e n t. In case of en-
doscopic treatment failure it is recommended to perform angiography combined 
with embolization. Surgical treatment for bleeding peptic ulcer niche is used as 
a last resort [2, 14, 20, 25].
Patients who manifest signs of bleeding and in case of failure to identify the 
source of bleeding, the endocapsule or enteroscopy should be used for small bowel 
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T a b l e  4
Blatchford scoring: admission risk markers and associated score component values [13].
Admission risk marker Score component value
Blood urea, mmol/L
6.5–≤8 2
8.0–<10.0 3
10.0–<25 4
≥25 6
Hemoglobin for men, g/dl
12.0–13.0 1
10.0–<12.0 3
<10.0 6
Hemoglobin for women, g/dl
10.0–<12.0 1
10.0 6
Systolic blood pressure, mm Hg
100–109 1
90–99 2
<90 3
Other markers
Pulse ≥100/min 1
Presentation with melena 1
Presentation with syncope 2
Hepatic disease 2
Cardiac failure 2
examination [2, 14]. Examination with endocapsule is non-invasive and it does 
not require sedation and in most cases permits to evaluate the whole intestine. 
The main drawback of this method is the inability to stop bleeding. 
Enteroscopy allows the exact location of a bleeding source and using one of 
the endoscopic methods to stop it, and in case of failure tattoo marking place 
before surgery. The effectiveness of this treatment depends mainly on the physi-
cian’s experience in endoscopic procedures. It is often hard to visualize the entire 
small intestine, the treatment requires a special, rarely available instrumentation, 
perforation of the GI tract or damage to the mesentery of the small intestine may 
occur during the examination. 
A proper selection of patients who can be safely discharged from the hospital is 
a major problem. These are patients below 60 years of age, hemodynamically stable, 
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without comorbidities, without coagulation disorders, with a hemoglobin level of 
greater than 8 g/dL, in whom bleeding occurred outside the hospital, and there was 
no active bleeding on endoscopy. They must be patients whose consciousness and 
material status can afford home treatment [2, 20, 25] (Table 5).
Age <60 years
No hemodynamic instability
No severe coexisting illness
A hemoglobin level over 8.0 g/dl after adequate vascular volume expansion
Normal coagulation studies
Onset of bleeding outside the hospital
Presence of a clean-based bleeding lesion
Adequate social support at home with an ability to return promptly to healthcare facility
T a b l e  5
Selection criteria for early hospital discharge (following early endoscopy) [1, 20, 21].
T a b l e  6
Endoscopic principles of management in nonvariceal upper GI bleeding [1, 20, 21].
Endoscopy should be performed within 24 hours that follow presentation when possible.
All patients exhibiting high-risk endoscopic stigmata should receive endoscopic hemostasis.
Highly selected patients at very low risk for rebleeding may be discharged home immediately 
after an early endoscopy.
Patients exhibiting a pigmented dot or clean base ulcer do not require endoscopic  
hemostasis.
Although better than doing nothing, epinephrine injection alone provides suboptimal  
efficacy and should be used in combination with another modality such as clips, thermal 
or sclerosant injection that are also efficacious alone.
Endoscopists should opt for an efficacious hemostatic method, with which they are more 
comfortable.
Finding a clot in an ulcer bed requires an attempt at dislodgement in order to treat  
the underlying lesion.
Optimal treatment of adherent clots remains controversial; endoscopic therapy should be 
considered but intensive PPI therapy may be sufficient.
Second-look endoscopy should be considered on a case-by-case basis if the effectiveness of 
endoscopic hemostasis is in question or for patients at particularly high risk of rebleeding.
BLEEDING PROPHyLAxIS
Helicobacter pylori infection and NSAIDs are the factors contributing to the oc-
currence of bleeding peptic ulcerations. Eradication of bacteria, avoiding NSAIDs, 
aspirin and clopidogrel reduces the possibility of bleeding. Eradication of Helico-
bacter pylori reduces the risk of distant recurrence of bleeding from 20% to 2.9%. 
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Effectiveness of eradication should be confirmed after treatment. Patients requir-
ing anticoagulant medications for cardiac and vascular reasons should take them 
under cover of PPI [2, 4, 9, 25]. 
BLEEDING RELATED TO PORTAL HyPERTENSION
The risk of bleeding increases when the portal-hepatic venous pressure gradient 
exceeds 12 mm Hg. Bleeding affects about 40–80% patients with liver cirrhosis 
and portal hypertension and the 6-week mortality rate after the first hemorrhage 
is about 50% [10, 14]. 
90% of patients with liver cirrhosis lasting 10 years or more bleed from esoph-
ageal varices. Esophageal variceal hemorrhage occurs most commonly, however 
in more than 10% of patients varices are located in the gastric fundus. Patients 
with large varices, covered with numerous red spots on the mucosa and decom-
pensated cirrhosis (Child-Pugh class C) may bleed into the lumen of GI tract in 
more than 70% of cases. It was observed that in nearly 25% of patients with 
cirrhosis and esophageal varices bleeding is caused by other pathology (usually 
peptic ulcer disease), and further 25% of patients present other lesions on en-
doscopy that may be the bleeding source [2].
Initial management consists of fluid resuscitation and evaluating the possi-
bility of liver failure. It is proposed to start the treatment from administration 
of synthetic somatostatin longer-acting analogue octreotide, causing selective 
visceral vasoconstriction. Octreotide is administered by intravenous infusion at 
a dose of 1–2 µg/kg/hour and applied for 3–5 days. Reducing the visceral flow 
via administration of beta-blockers in case of active bleeding as an isolated pro-
cedure is not effective, but their use in patients after elective repeated endoscopic 
procedures reduces the rate of rebleeding. It is also desirable to provide vitamin 
K and fresh frozen plasma in order to improve blood coagulation. Endoscopy is 
performed immediately, preferably up to 12 hours from the onset of hemorrhage. 
The procedure is significantly hindered by massive blood pouring out of one or 
more varices and shutting out the view of the endoscope. Endoscopic variceal li-
gation has been shown to be more efficacious than sclerotherapy. Rubber band 
ligation is performed on several levels, as well as injection of a vasoconstrictive 
agent. The efficacy of endoscopic cessation of bleeding is assessed at 75–95%, 
but more than 30% of patients suffer from recurrent bleeding. Because infections 
are common in patients with bleeding varices, prophylactic antibiotics are initi-
ated. They have been shown to decrease the infection rate by more than 50%, 
decrease rebleeding, and improve survival [14, 28].
If a temporary bleeding cessation is achieved, endoscopic procedures are re-
peated several times in a planned manner at 2 week intervals. Reduction of re-
bleeding rate develops after 3–4 sessions. 
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If endoscopic methods are not effective, it is necessary to perform mechani-
cal tamponade. Tamponade is made using special probes with two filled balloons 
(gastric and esophageal) and the suction channel for gastric contents (Sengstaken- 
Blakemore probe). The effectiveness of this method in immediate cessation of 
bleeding is 94% but recurrent hemorrhage occurs in 60% of patients after bal-
loon deflation. The probe can be kept inflated in the esophagus up to 24 hours.
SUMMARy
In the last few years treatment tactic of upper GI bleeding changed radically. The 
combination of endoscopy and pharmacotherapy reduced mortality in patients 
suffering from acute GI hemorrhage. Endoscopy performed early, up to 24 hours 
permits to recognize the source of bleeding, stop it and identify the patients more 
vulnerable to the risk of recurrent bleeding. The use of multiple endoscopic meth-
ods for bleeding control together with eradication of Helicobacter pylori and high 
doses of PPI decreased the recurrence rate of bleeding along with the amount 
of emergency surgical procedures. Strict indications for blood transfusion had 
a positive impact on the outcomes of treatment. Future research will focus mainly 
on bleeding prevention and on the treatment of elderly patients, receiving anti-
coagulants and anti–inflammatory drugs.
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